Serum levels of insulin-like growth factor 1 are negatively associated with log transformation of thyroid-stimulating hormone in Graves' disease patients with hyperthyroidism or subjects with euthyroidism: A prospective observational study
- PMID: 30882687
- PMCID: PMC6426554
- DOI: 10.1097/MD.0000000000014862
Serum levels of insulin-like growth factor 1 are negatively associated with log transformation of thyroid-stimulating hormone in Graves' disease patients with hyperthyroidism or subjects with euthyroidism: A prospective observational study
Abstract
Insulin-like growth factor 1 (IGF-1) has a molecular structure similar to that of insulin. As an essential mediator of growth hormone, IGF-1 plays a vital role in growth of children and anabolic effects of adults. We evaluated the serum levels of IGF-1 in patients with hyperthyroidism or euthyroidism.In this study, 30 patients each of Graves' disease with hyperthyroidism (HY group) and euthyroid individuals (EU group) were recruited. The HY patients were treated with antithyroid regimens as clinically indicated. No medications were given to EU patients. The demographic characteristics and anthropometric and laboratory data of both groups at baseline and 6 months were compared. Associations between levels of IGF-1 and free thyroxine (fT4), thyroid-stimulating hormone (TSH), or log transformation of TSH (logTSH) were analyzed.At baseline, the HY patients had significantly higher serum IGF-1 levels than EU patients (median [Q1, Q3]: 305.4 [257.4, 368.1] vs. 236.7 [184.6, 318.8] ng/mL, P = .007). At 6 months, the HY patients still had higher serum levels of IGF-1 than EU patients (299.5 [249.9, 397.9] vs 222.1 [190.2, 305.4] ng/mL, P = .003). At baseline, the serum levels of IGF-1 in the HY and EU patients were positively associated with fT4 (β = 29.02, P = .002) and negatively associated with TSH (β = -31.46, P = .042) and logTSH (β = -29.04, P = .007). The associations between serum levels of IGF-1 with fT4 or TSH became insignificant at 6 months. However, the serum IGF-1 levels had persistent negative associations with logTSH at 6 months (β = -26.65, P = .021). The negative associations between IGF-1 and logTSH at baseline and 6 months remained significant even after adjustment with sex and age (β = -20.22, P = .023 and β = -20.51, P = .024, respectively).The HY patients had higher serum IGF-1 levels than EU patients. The serum IGF-1 concentrations were negatively associated with logTSH in patients with hyperthyroidism or euthyroidism.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Serum levels of fetuin-A are negatively associated with log transformation levels of thyroid-stimulating hormone in patients with hyperthyroidism or euthyroidism: An observational study at a medical center in Taiwan.Medicine (Baltimore). 2018 Nov;97(46):e13254. doi: 10.1097/MD.0000000000013254. Medicine (Baltimore). 2018. PMID: 30431610 Free PMC article.
-
Serum Levels of Follistatin Are Positively Associated With Serum-Free Thyroxine Levels in Patients With Hyperthyroidism or Euthyroidism.Medicine (Baltimore). 2016 Feb;95(5):e2661. doi: 10.1097/MD.0000000000002661. Medicine (Baltimore). 2016. PMID: 26844494 Free PMC article.
-
Insulin-like growth factor-binding protein-3 (IGFBP-3) but not insulin-like growth factor-I (IGF-I) remains elevated in euthyroid TSH-suppressed Graves' disease.Horm Metab Res. 1998 Apr;30(4):213-6. doi: 10.1055/s-2007-978868. Horm Metab Res. 1998. PMID: 9623636
-
Serum Spot 14 concentration is negatively associated with thyroid-stimulating hormone level.Medicine (Baltimore). 2016 Oct;95(40):e5036. doi: 10.1097/MD.0000000000005036. Medicine (Baltimore). 2016. PMID: 27749565 Free PMC article.
-
Growth hormone/insulin-like growth factor axis in patients with subclinical thyroid dysfunction.Growth Horm IGF Res. 2009 Jun;19(3):252-5. doi: 10.1016/j.ghir.2008.11.003. Epub 2008 Dec 25. Growth Horm IGF Res. 2009. PMID: 19111490
Cited by
-
A Comparative Follow-Up Study of Patients with Papillary Thyroid Carcinoma Associated or Not with Graves' Disease.Diagnostics (Basel). 2022 Nov 15;12(11):2801. doi: 10.3390/diagnostics12112801. Diagnostics (Basel). 2022. PMID: 36428861 Free PMC article.
-
Teprotumumab-associated chronic hearing loss screening and proposed treatments.BMJ Case Rep. 2022 Apr 13;15(4):e248335. doi: 10.1136/bcr-2021-248335. BMJ Case Rep. 2022. PMID: 35418378 Free PMC article.
-
IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome.Cell Rep. 2022 Dec 27;41(13):111883. doi: 10.1016/j.celrep.2022.111883. Cell Rep. 2022. PMID: 36577365 Free PMC article.
-
Growth hormone-secreting pituitary adenoma combined with Graves' disease: retrospective case series and literature review.Endocr Connect. 2024 Mar 4;13(4):e230439. doi: 10.1530/EC-23-0439. Print 2024 Apr 1. Endocr Connect. 2024. PMID: 38349236 Free PMC article.
-
Analysis of epidemiological association patterns of serum thyrotropin by combining random forests and Bayesian networks.PLoS One. 2022 Jul 21;17(7):e0271610. doi: 10.1371/journal.pone.0271610. eCollection 2022. PLoS One. 2022. PMID: 35862421 Free PMC article.
References
-
- Silva JE. The thermogenic effect of thyroid hormone and its clinical implications. Ann Intern Med 2003;139:205–13. - PubMed
-
- Völzke H, Friedrich N, Schipf S, et al. Association between serum insulin-like growth factor-I levels and thyroid disorders in a population-based study. J Clin Endocrinol Metab 2007;92:4039–45. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous